Risk management for analytical methods based on the total error concept: Conciliating the objectives of the pre-study and in-study validation phases

In industries that involve either chemistry or biology, analytical methods are necessary to keep an eye on all the material produced. If the quality of an analytical method is doubtful, then the whole set of decisions based on those measures is questionable. For this reason, being able to assess the quality of an analytical method is far more than a statistical challenge; it is a matter of ethics and good business practices. The validity of an analytical method must be assessed at two levels. The "pre-study" validation aims to show, by an appropriate set of designed experiments, that the method is able to achieve its objectives. The "in-study" validation is intended to verify, by inserting QC samples in routine runs, that the method remains valid over time. At these two levels, the total error approach considers a method as valid if a sufficient proportion of analytical results are expected to lie in a given interval around the (unknown) nominal value. This paper discusses two methods, based on this total error concept, of checking the validity of a measurement method at the pre-study level. The first checks whether a tolerance interval for hypothetical future measurements lies within given acceptance limits; the second calculates the probability of a result lying within these limits and computes, whether it is greater than a given acceptance level. For the "in-study" validation, the paper assesses the properties of the s-n-lambda rule recommended by the FDA. The properties and respective advantages and limitations of these methods are investigated. A crucial point is to ensure that the decisions taken at the pre-study stage and in routine use are coherent. More precisely, a laboratory should not see its method rejected in routine use when it has been proved to be valid and remains so. This paper shows how this goal may be achieved by choosing compatible validation parameters at both pre- and in-study levels. (c) 2006 Elsevier B.V. All rights reserved.

[1]  Philippe Hubert,et al.  The SFSTP guide on the validation of chromatographic methods for drug bioanalysis: from the Washington Conference to the laboratory , 1999 .

[2]  Robert W. Mee β-Expectation and β-Content Tolerance Limits for Balanced One-Way ANOVA Random Model , 1984 .

[3]  Philippe Hubert,et al.  Objectives of pre-study validation and decision rules , 2000 .

[4]  Fred Spiring,et al.  Introduction to Statistical Quality Control , 2007, Technometrics.

[5]  M Laurentie,et al.  Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal--part II. , 2004, Journal of pharmaceutical and biomedical analysis.

[6]  Krys J. Miller,et al.  Workshop on Bioanalytical Methods Validation for Macromolecules: Summary Report , 2001, Pharmaceutical Research.

[7]  Patrice Chiap,et al.  Méthodes chromatographiques de dosage dans les milieux biologiques : Stratégie de validation , 1996 .

[8]  J. W. Findlay,et al.  Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. , 2000, Journal of pharmaceutical and biomedical analysis.

[9]  W C Smith,et al.  Conceptual and statistical issues in the validation of analytic dilution assays for pharmaceutical applications. , 1998, Journal of biopharmaceutical statistics.

[10]  D L Massart,et al.  Validation of bioanalytical chromatographic methods. , 1998, Journal of pharmaceutical and biomedical analysis.

[11]  P. Chiap,et al.  An analysis of the SFSTP guide on validation of chromatographic bioanalytical methods: progress and limitations. , 2003, Journal of pharmaceutical and biomedical analysis.

[12]  David Hoffman,et al.  TWO-SIDED TOLERANCE INTERVALS FOR BALANCED AND UNBALANCED RANDOM EFFECTS MODELS , 2005, Journal of biopharmaceutical statistics.

[13]  Vinod P. Shah,et al.  Bioanalytical Method Validation—A Revisit with a Decade of Progress , 2000, Pharmaceutical Research.

[14]  G. B. Wetherill,et al.  Quality Control and Industrial Statistics , 1975 .

[15]  Binodh DeSilva,et al.  Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.

[16]  Philippe Hubert,et al.  Analyse statistique des résultats de validation de méthodes d’analyse chromatographiques , 2000 .

[17]  Robert W. Mee Estimation of the percentage of a normal distribution lying outside a specified interval , 1988 .

[18]  Robert W. Mee β-Expectation and β-Content Tolerance Limits for Balanced One-Way ANOVA Random Model@@@b-Expectation and b-Content Tolerance Limits for Balanced One-Way ANOVA Random Model , 1984 .

[19]  Robert O. Kringle,et al.  An Assessment of the 4-6-20 Rule for Acceptance of Analytical Runs in Bioavailability, Bioequivalence, and Pharmacokinetic Studies , 1994, Pharmaceutical Research.

[20]  Caporal-Gautier,et al.  Guide de validation analytique. Rapport d'une commission SFSTP. I : Méthodologie , 1992 .

[21]  Philippe Hubert,et al.  Conciliating objectives of analytical methods and objectives of validation : a statistical perspective , 2006 .